Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy in Eyes with Refractory Glaucoma: A Case Series
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This prospective observational case series study included 6 eyes of 6 consecutive glaucomatous patients. Each patient underwent trabeculectomy with mitomycin C, and received a 1.25 mg of subconjunctival bevacizumab injection at completion of the trabeculectomy. Study eyes included two with neovascular glaucoma, three with uveitic glaucoma, and one with secondary glaucoma following vitrectomy. All eyes had undergone failed glaucoma laser/surgical treatment or an intraocular surgical procedure. Intraocular pressure (IOP) at the following postoperative visits: preoperative, 1 week, 1 month, 2 months, 3 months, and 6 months, was measured. We also evaluated postoperative bleb findings and complications. IOP measured at each visit was 37.5±14.4 mmHg, 6.2±3.4 mmHg, 8.3±7.2 mmHg, 12.0±4.4 mmHg, 10.8±3.1 mmHg, and 12.2±3.3 mmHg, respectively, for each visit. All eyes had functioning blebs with normal IOP at postoperative 6 months with no additional IOP-lowering medication.
Abstract
This prospective observational case series study included 6 eyes of 6 consecutive glaucomatous patients. Each patient underwent trabeculectomy with mitomycin C, and received a 1.25 mg of subconjunctival bevacizumab injection at completion of the trabeculectomy. Study eyes included two with neovascular glaucoma, three with uveitic glaucoma, and one with secondary glaucoma following vitrectomy. All eyes had undergone failed glaucoma laser/surgical treatment or an intraocular surgical procedure. Intraocular pressure (IOP) at the following postoperative visits: preoperative, 1 week, 1 month, 2 months, 3 months, and 6 months, was measured. We also evaluated postoperative bleb findings and complications. IOP measured at each visit was 37.5±14.4 mmHg, 6.2±3.4 mmHg, 8.3±7.2 mmHg, 12.0±4.4 mmHg, 10.8±3.1 mmHg, and 12.2±3.3 mmHg, respectively, for each visit. All eyes had functioning blebs with normal IOP at postoperative 6 months with no additional IOP-lowering medication.
참고문헌 (22)
- Gan L, "Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing", Acta Ophthalmol Scand, 82, pp.557~563 (2004)
- Presta LG, "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders", Cancer Res, 57, pp.4593~4599 (1997)
- Miller KD, "Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer", J Clin Oncol, 23, pp.792~799 (2005)
- Rich RM, "Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration", Retina, 26, pp.495~511 (2006)
- Avery RL, "Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy", Ophthalmology, 113, pp.1695~
- Wakabayashi T, "Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases", Ophthalmology, 115, pp.1571~1580 (2008)
- Manzano RP, "Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)", Br J Ophthalmol, 91, pp.804~807 (2007)
- Kim SW, "The effect of topical bevacizumab on corneal neovascularization", Ophthalmology, 115, pp.e33~e38 (2008)
- Wilgus TA, "Regulation of scar formation by vascular endothelial growth factor", Lab Invest, 88, pp.579~590 (2008)
- Li Z, "Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery", Invest Ophthalmol Vis Sci, 50, pp.5217~5225 (2009)
- Jonas JB, "Intravitreal bevacizumab for filtering surgery", Ophthalmic Res, 39, pp.121~122 (2007)
- Grewal DS, "Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy: a pilot study", Ophthalmology, 115, pp.2141~2145 (2008)
- Lama PJ, "Antifibrotics and wound healing in glaucoma surgery", Surv Ophthalmol, 48, pp.314~346 (2003)
- Jordan JF, "Photodynamic modulation of wound healing in glaucoma filtration surgery", Br J Ophthalmol, 87, pp.870~875 (2003)
- Lu DW, "Wound modulation after trabeculectomy by different formulations of antimeta- bolites in rabbits", J Ocul Pharmacol Ther, 16, pp.529~538 (2000)
- Demir T, "Effects of octreotide acetate and amniotic membrane on wound healing in expe- rimental glaucoma surgery", Doc Ophthalmol, 107, pp.87~92 (2003)
- Chaudhary NI, "Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis", Eur Respir J, 29, pp.976~985 (2007)
- Vote B, "Systemic anti-inflammatory fibrosis suppression in threatened trabeculectomy failure", Clin Experiment Ophthalmol, 32, pp.81~86 (2004)
- Bock F, "Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis", Invest Ophthalmol Vis Sci, 48, pp.2545~2552 (2007)
- Wu WS, "Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation", J Invest Dermatol, 126, pp.1264~1271 (2006)
- Zhang N, "Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse", Blood, 103, pp.617~626 (2004)
- Memarzadeh F, "Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit", Invest Ophthalmol Vis Sci, 50, pp.3233~3237 (2009)